2027 Medicare cost increases could change patient behavior before the first refill is due
Medicare beneficiaries are heading into 2027 with a very specific financial squeeze: higher drug costs, higher medical premiums and larger deductibles arriving at the same time. For many patients with chronic disease, the practical effect will not be a tidy line item on a benefits statement. It will be a skipped refill, a delayed follow-up, or a referral pushed off until “later.”
That behavioral shift matters because cost-related nonadherence is not a neutral choice. When patients stop statins, antihypertensives, anticoagulants, inhalers or other maintenance therapies, the biological consequences accumulate quietly until they arrive in clinic as a more expensive problem. In risk-bearing arrangements, the first-quarter dip in utilization may look like savings. In reality, it may be deferred care waiting to reappear in the summer or fall.
The biggest pressure points are concentrated in January
The sharpest strain begins at the start of the plan year, when patients refill long-term medications and face fresh deductibles before any routine medical care has had a chance to stabilize. The standard Part D deductible is projected to rise 13.8% to $700, while the Part B premium is projected to increase by $6.60 to $209.50 and the Part B deductible by $9 to $292. The Part D out-of-pocket cap also rises, from $2,100 to $2,400.
For patients who were in $0-premium standalone drug plans in 2026, the end of the premium stabilization demonstration changes the calculation even more. In 2026, 4 million non-Extra Help enrollees paid nothing for a standalone drug plan. KFF estimates that keeping current plans could push the average standalone premium from $34 to $51 a month, with 2.4 million people facing increases of more than $50. The more than 2 million non-Extra Help enrollees in UnitedHealthcare’s AARP-branded plans face increases of $50 or more in most states if they stay.
A beneficiary with traditional Medicare and Plan G who had been paying zero for Part D could face roughly $41 to $67 in higher monthly costs once the Part B premium, Medigap premium and drug premium are combined. The 3.6% Social Security COLA may offset that on paper, but the increase does not erase inflation already absorbed through food, transportation and fuel. For rural patients, gasoline increases can be enough to change whether a visit happens at all.
Lower utilization can look like efficiency while hiding future cost
The financial risk is not limited to patients. It also lands on practices and Medicare Advantage organizations that are paid to manage total cost of care. If a patient misses a January refill or skips a follow-up, the claims file may simply show lower activity. The disease process, however, keeps advancing.
Chronic conditions are especially vulnerable to this pattern because they do not need a dramatic trigger to worsen. Blood pressure creeps up, lipids rise, glucose control drifts, edema worsens and symptoms are normalized until the patient finally seeks care. In cardiovascular disease and diabetes, months of medication interruption can mean a preventable hospitalization. In pulmonary disease, a missed inhaler refill can become an exacerbation. In kidney disease, the cost of delayed management is often measured later in laboratory deterioration and avoidable acute care.
The article’s central warning is a timing mismatch: what looks favorable in early 2027 may simply be the absence of care that would have surfaced claims later. That is a dangerous illusion for organizations managing downside risk. A smaller January claims run does not necessarily mean healthier patients; it may mean patients are rationing care they can no longer afford.
The patients most exposed are the ones closest to the subsidy thresholds
About 13.6 million Part D enrollees receiving Extra Help are largely protected. The program eliminates the deductible, subsidizes premiums up to a benchmark and caps copays. Dual eligibles and Medicare Savings Program enrollees are automatically deemed eligible.
Exposure rises for beneficiaries just above those thresholds. Many Medicare Advantage enrollees are also affected, because about 70% are expected to face higher out-of-pocket maximums in 2027. KFF projects the average MA drug deductible will rise from $360 to $489. A patient on a costly maintenance regimen may feel the same January pressure whether coverage is in traditional Medicare or Medicare Advantage.
Rural patients, people on fixed incomes and those with transportation barriers are likely to feel the sharpest practical effect. Even a modest monthly premium increase can change refill timing, particularly when the annual deductible lands before any physician visit has a chance to reinforce adherence. The workflow implication is immediate: screening for Extra Help and Medicare Savings Program eligibility is not just a benefits task anymore. It is part of chronic disease management.
Payment rules can make deferred care harder to detect
CMS is also changing how Medicare Advantage risk scores will be built in 2027 by excluding diagnoses from unlinked chart reviews and audio-only encounters. The policy matters because diagnosis capture is tied directly to revenue and planning. When a visit does not happen, the diagnosis may never be documented. When a phone check-in no longer fills the gap, organizations can lose both clinical visibility and financial signal.
That creates a second-order problem for practices and plans. Lower utilization from deferred care can reduce next year’s risk adjustment even as patients return sicker. The result is not just missed revenue; it is a distorted picture of population health. Organizations that rely on early-year utilization data without separating true improvement from access barriers may understate the care burden they will face later.
Practices need a patient-level response before the plan year turns
Before Dec. 7, practices should identify patients whose coverage changes place them at risk. The most obvious candidates are those taking expensive maintenance medications, those just above the Extra Help threshold and those with a history of missed appointments or transportation problems. Patients can be directed to a State Health Insurance Assistance Program, 1-800-MEDICARE or another trusted benefits counselor for neutral guidance. Medicare Advantage shoppers should review network access, prior authorization requirements and medication-specific out-of-pocket costs, not just premiums.
The conversation should stay centered on total cost, because a low premium can hide a high deductible or restrictive formulary. CMS marketing rules limit steering, but clinicians can still discuss the practical consequences of coverage choices and encourage patients to compare what they will actually pay for their own medication list.
January outreach should focus on the first missed refill or visit
In January, the most useful operational step is a proactive outreach list for chronic care patients who miss a refill or a follow-up. Someone on the team needs to own that process. Chronic care management and advanced primary care management billing can help support the time required, but the work has to be assigned deliberately.
Staff should also understand the temporary transition supply available to new plan enrollees when a medication is not covered. Patients need that information early, before they abandon therapy entirely. The Medicare Prescription Payment Plan may also help some beneficiaries by spreading the $700 deductible across the year. It does not reduce the amount owed, but it can make a first fill possible when a lump-sum bill would have stopped treatment.
MA enrollees retain a limited window to switch plans or return to traditional Medicare once between Jan. 1 and March 31. For some patients, that escape hatch will matter more than any brochure released during open enrollment.
Finance teams should resist calling early savings real savings
Contracting and finance staff should not treat first-quarter efficiency as durable until the underlying utilization pattern is clear. Lower spending in January may reflect better health, but it may also reflect drugs not picked up, referrals not made and procedures postponed. Benchmarks and quality programs need to be reviewed with that in mind, especially where suppressed utilization can make performance look stronger than it is.
Tracking should be monthly, not annual: prescription abandonment, no-shows, delayed referrals and procedure deferrals should all be monitored by payer and by vulnerability status. If the pattern is caught early, practices can intervene before the missed refill becomes the admission. If it is missed, the cost will often surface months later, when the patient finally returns with a more advanced problem.